头颈部鳞状细胞癌根治性放疗或放化疗后早期非肿瘤死亡风险预测
该研究基于丹麦头颈癌协作组数据库纳入2010—2017年在Rigshospitalet或Herlev医院接受根治性放疗或放化疗(含术后)的2209例头颈部鳞状细胞癌患者,构建预测180天内非头颈癌死亡风险的模型。180天非头颈癌死亡率为4.4%,肺炎占非头颈癌死亡的31.6%;内部验证曲线下面积0.74(95%CI 0.66-0.81),0%~20%风险范围内校准良好。作者认为该工具可用于筛选高危患者以开展支持性干预。
要点
- 2209例接受根治性放疗或放化疗的头颈部鳞癌患者中,180天非头颈癌死亡率为4.4%。
- 非头颈癌死亡中近三分之一(31.6%)由肺炎引起。
- 预测模型内部验证AUC为0.74(95%CI 0.66-0.81),0%~20%风险范围校准良好。
核心结论
- 作者开发了预测头颈部鳞状细胞癌患者放疗或放化疗开始后180天内非头颈癌死亡风险的工具,认为可用于筛选高危患者以开展旨在提高生存率的支持性干预。
研究设计与样本
- 基于丹麦头颈癌协作组(DAHANCA)数据库,纳入2010—2017年在Rigshospitalet或Herlev医院接受根治性放疗或放化疗(含术后放疗或放化疗)的头颈部鳞状细胞癌患者2209例。
- 预测变量包括年龄、分期、体能状态、肿瘤亚部位(含p16状态)、合并症、术后状态、吸烟及治疗前白蛋白水平,采用病因特异性Cox回归模型组合估计180天非头颈癌死亡风险。
主要发现
- 180天非头颈癌死亡率为4.4%。
- 非头颈癌死亡中31.6%由肺炎引起。
- 内部模型验证的受试者工作特征曲线下面积为0.74(95%CI 0.66-0.81),0%至20%风险预测范围内校准良好。
临床怎么用
- 作者认为该预测工具可用于筛选高危患者以开展旨在提高生存率的支持性干预,并在https://emriskpred.shinyapps.io/EMNED_App/提供交互使用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In patients with head and neck squamous cell carcinoma (HNSCC), curative-intent radiotherapy (RT) and chemoradiotherapy (CRT) are associated with substantial acute morbidity and 5-10% of patients die within 180 days of treatment initiation. Most of these early deaths occur without HNSCC recurrence or progression and may therefore be preventable to some extent. We developed a prediction tool to estimate the risk of non-HNSCC mortality occurring within the first 180 days followingRT/CRT initiation. METHODS: Patients with HNSCC treated with RT/CRT, including postoperative RT/CRT, at Rigshospitalet or Herlev Hospitals between 2010-2017 were identified in the Danish Head and Neck Cancer Group (DAHANCA) database. Predictor variables included age, stage, performance status, tumor subsite including p16 status, comorbidity, postoperative status, smoking and pre-treatment albumin levels. The 180-day non-HNSCCmortality risk was estimated by combining cause-specific Cox regression models. RESULTS: We included 2209 patients. The 180-day non-HNSCCmortality rate was 4.4% and almostone third (31.6%) of non-HNSCCdeathswere caused by pneumonia.After internal model validation, the area under the receiver operating curve was 0.74 (95% CI: 0.66-0.81) and calibration was good for risk predictions ranging from 0% to 20%. CONCLUSION: We developed a prediction tool to estimate the 180-day non-HNSCC mortality risk. This tool can be used to select high-risk patients for supportive interventions aiming to improve survival rates, and is availablefor interactive use at https://emriskpred.shinyapps.io/EMNED_App/.
引用
- Jensen KH, Vogelius IR, Bernsdorf M, et al. Early non-cancer mortality risk prediction after curative-intent radiotherapy or chemoradiotherapy for head and neck squamous cell carcinoma. Radiother Oncol. 2022. PMID: 35395275. doi:10.1016/j.radonc.2022.03.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。